Press Release

Lengo Therapeutics Announces Appointment of Brion W. Murray, Ph.D., as Senior Vice President of Research

November 1, 2021

SAN DIEGO--(BUSINESS WIRE)-- Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Brion W. Murray, Ph.D., as Senior Vice President of Research.

Dr. Murray brings more than 25 years of life sciences experience discovering and developing oncology therapies. Prior to Lengo, he was Vice President, Cancer Biology & Translational Research at Turning Point Therapeutics where he led the discovery teams which contributed to two new molecular entities, multiple drug combination clinical trials, and the initiation of four drug discovery programs. At Pfizer, he was a Research Fellow and contributed to the discovery and/or development of six FDA approved oncology drugs, including Inyta, Bosulif, Xalkori, Vizimpro, Ibrance and Sutent. He was also a project leader or discipline leader on teams that created twelve development candidates at Pfizer.

"Dr. Murray is a talented research executive with an impressive record of accomplishments in oncology drug discovery and development. We are excited to welcome him to Lengo and look forward to working with him to expand our pipeline of precision medicines targeting driver mutations in oncology," said Enoch Kariuki, Pharm.D., Chief Executive Officer at Lengo Therapeutics.

“I look forward to working with Enoch and members of the Lengo management team to drive a world-class R&D program and advance novel precision oncology therapeutics for patients with significant unmet medical need,” said Brion W. Murray, Ph.D., Senior Vice President of Research, Lengo Therapeutics.

Dr. Murray has made fundamental scientific discoveries in the fields of biochemistry, cellular signaling, cancer biology, and pharmacology, resulting in numerous top-tier publications and patents. He serves as a senior editor for American Association of Cancer Research journal Molecular Cancer Therapeutics and is a founding member of the Chemical Biology division of the Faculty of 1000 (now Faculty Opinions). He received a B.S in Chemistry from the University of North Carolina, Chapel Hill, a Ph.D. in Biochemistry from the University of Maryland, and was a post-doctoral fellow at The Scripps Research Institute.

About Lengo Therapeutics

Lengo Therapeutics is a biopharmaceutical company committed to developing novel, precision medicines targeting driver mutations in oncology. Lengo has assembled a team of scientists and industry leaders with extensive expertise in kinase biology, covalent drug-target technology and oncology drug development. The company’s vision is to develop a pipeline of investigational candidates that can offer benefit to patients with cancers harboring driver mutations. Lengo Therapeutics is based in San Diego. For more information, please visit www.lengotx.com.

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com